Related Experiment Videos
Pharmacologic approaches to therapy for vasovagal syncope
1Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
The American Journal of Cardiology
|November 24, 1999
Summary
Vasovagal syncope management is complex. Only atenolol, midodrine, and paroxetine show proven efficacy in randomized trials for this common autonomic disorder.
Area of Science:
- Cardiology
- Neurology
- Autonomic Neuroscience
Background:
- Vasovagal syncope is a prevalent condition affecting autonomic cardiovascular regulation.
- Numerous medications are suggested for vasovagal syncope based on limited evidence.
- Robust clinical trial data is crucial for treatment validation.
Purpose of the Study:
- To review and summarize evidence for pharmacologic treatments of vasovagal syncope.
- To evaluate the efficacy of agents based on prospective, randomized, placebo-controlled trials.
- To provide clarity on current treatment options for vasovagal syncope.
Main Methods:
- Literature review of clinical trials on vasovagal syncope pharmacotherapy.
- Focus on prospective, randomized, placebo-controlled studies.
- Analysis of data supporting or refuting treatment efficacy.
Main Results:
- Atenolol, midodrine, and paroxetine are the only agents with demonstrated efficacy in at least one randomized trial.
- Many other commonly used therapies lack strong supporting evidence from rigorous trials.
- Data supporting fludrocortisone and increased salt/fluid intake was also considered.
Conclusions:
- Evidence supports the use of atenolol, midodrine, and paroxetine for vasovagal syncope.
- Further high-quality research is needed for other proposed treatments.
- This review aids clinicians in selecting evidence-based therapies for vasovagal syncope.